Aspire Biopharma Holdings, Inc. (ASBP) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, Aspire Biopharma reported revenue of $6,202. Net income was -$24.5M (a -394725.1% net margin), or -$16.38 per diluted share. Gross margin was -1.9% and operating margin was -312016.9%. Operating activities generated -$4.9M of cash. At fiscal year end, Aspire Biopharma held $1.3M in total assets against $7.7M in total liabilities.
Open the full interactive Aspire Biopharma financials → Quarterly statements, key ratios, valuation history and price charts.
Aspire Biopharma Key Stats
| Share Price | $8.18 |
|---|---|
| Market Cap | $8.5M |
| 52-Week Range | $0.16 – $17.80 |
| Shares Outstanding | 1.0 million (basic, 2026 Q2) |
Aspire Biopharma Income Statement
| FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $6,202 |
| Cost of Goods Sold | — | — | — | $6,318 |
| Gross Profit | — | — | — | -$116 |
| Operating Income | — | — | — | -$19.4M |
| Pre-Tax Income | $3.3M | $4.5M | -$12.5M | -$24.5M |
| Net Income | $3.3M | $4.5M | -$12.5M | -$24.5M |
| Diluted EPS | $4.40 | $9.20 | -$60.80 | -$16.38 |
Aspire Biopharma Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $1,941 | $4,261 | $28,353 | $63,104 |
| Net Income | -$1.9M | -$4.7M | -$3.2M | -$1.3M |
| Diluted EPS | -$1.60 | -$3.15 | -$20.57 | -$1.22 |
Aspire Biopharma Balance Sheet
| FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|
| Current Assets | $1.1M | $81,223 | $45,842 | $1.3M |
| Total Assets | $300.2M | $20.0M | $6.7M | $1.3M |
| Current Liabilities | $303,323 | $403,328 | $15.6M | $7.6M |
| Total Long-Term Debt | — | — | $465,722 | $1.4M |
| Total Liabilities | $11.1M | $403,328 | $15.6M | $7.7M |
| Shareholders' Equity | -$9.9M | -$322,105 | -$15.6M | -$6.4M |
Aspire Biopharma Cash Flow Statement
| FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|
| Cash From Operations | -$1.4M | -$653,107 | -$2.1M | -$4.9M |
| Cash From Investing | -$294.7M | $284.9M | $13.8M | — |
| Cash From Financing | $296.6M | -$284.8M | -$11.7M | $5.9M |
Figures from Aspire Biopharma's 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Aspire Biopharma financials page for every line item.
Aspire Biopharma Company Profile
| Ticker | ASBP |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | Estero, Florida |
| Fiscal Year End | December 31 |
| SEC Filer Category | Emerging growth company |
| SEC CIK | 0001847345 |
Frequently Asked Questions
What was Aspire Biopharma's revenue in fiscal 2025?
Aspire Biopharma (ASBP) reported revenue of $6,202 for fiscal 2025.
What is Aspire Biopharma's annual revenue history?
Aspire Biopharma's annual revenue by fiscal year: 2022: $0; 2023: $0; 2024: $0; 2025: $6,202.
What was Aspire Biopharma's net income in fiscal 2025?
Aspire Biopharma reported net income of -$24.5M for fiscal 2025.
What was Aspire Biopharma's earnings per share (EPS) in fiscal 2025?
Aspire Biopharma's diluted EPS was -$16.38 for fiscal 2025 (adjusted for any later stock splits).
What was Aspire Biopharma's revenue last quarter?
In its most recent reported quarter (2026 Q2), Aspire Biopharma reported revenue of $63,104.
How much debt does Aspire Biopharma have?
Aspire Biopharma reported $1.4M of long-term debt, including the current portion, at the end of fiscal 2025.
How many shares of Aspire Biopharma are outstanding?
Aspire Biopharma reported a weighted average of 1.0 million basic shares outstanding in 2026 Q2.
What is Aspire Biopharma's market cap?
Based on its latest closing price, Aspire Biopharma (ASBP) has a market capitalization of about $8.5M.
When does Aspire Biopharma's fiscal year end?
Aspire Biopharma's fiscal year end, as registered with the SEC, is December 31.
Where is Aspire Biopharma headquartered?
Aspire Biopharma lists its business address in Estero, Florida in its SEC filings.